Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cardio Diagnostics Holdings, Inc. (CDIO)

Cardio Diagnostics regains Nasdaq minimum bid price compliance after 10 days above $1.00

Neutral Impact 2 of 5 legal/regulatory Written later

Cardio Diagnostics Holdings received written notice from Nasdaq on May 28, 2025, that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The closing bid price was $1.00 or greater for the 10 consecutive business days from May 13 through May 27, 2025. The notice removes the risk of delisting that had been pending under the extended compliance period ending June 2, 2025.

Key points

  • Nasdaq notice dated May 28, 2025 confirms regained compliance with the minimum bid price rule (Listing Rule 5550(a)(2)).
  • Compliance is based on closing bid prices of $1.00 or greater from May 13, 2025 through May 27, 2025.
  • The company had been given until June 2, 2025 to regain compliance, following an initial December 2, 2024 deadline.
  • The non-compliance notice was first received on June 3, 2024.

The filing

CompanyCardio Diagnostics Holdings, Inc. (CDIO)
Form8-K, current report
Filed with the SECMay 28, 2025, 4:30 PM ET
Accession number0001079973-25-000937

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 28, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.